Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists investigate immune cells in Horton's disease

NCT ID NCT02158208

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a type of immune cell called T CD8 plays a role in Horton's disease, a condition that causes inflammation in blood vessels. Researchers took extra blood samples and performed standard tests on 30 newly diagnosed patients to measure these immune cells. The goal was to gather information, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Jul 2013

Finished

Jan 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting Horton's disease at the diagnosis before any treatment

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients * Patients who have provided written informed consent * Patients covered by national health insurance * Age \> 50 years * Patients with Horton's disease at the diagnosis before any treatment Horton's disease is defined by American College of Rheumatology criteria, the diagnosis is made if any 3 of the following 5 criteria are associated: * age at the onset of the disease 50 years or above * recent onset localised headache * indurated temporal artery or decrease/absence of temporal pulse * erythrocyte sedimentation rate (ESR) above 50 mm for the first hour (or CRP\>20 mg/L) * positive TAB showing vascularitis with infiltration of mononucleated cells or granulomatous inflammation with or without giant cells. Controls Controls will be healthy volunteers recruited from blood donors of Dijon CHU, voluntary hospital personnel (nurses, doctors, laboratory technicians and secretaries) and patients without infectious or inflammatory disease, cancer or auto-immune disease (CRP\<5mg/L) recruited in the department of the investigators at Dijon CHU. They will be matched for age and sex. * Age \> 50 years * Patients covered by national health insurance * who have provided written informed consent to take part * Absence of inflammatory syndrome (CRP\<5 mg /L) Exclusion Criteria: * Any patient not meeting inclusion criteria * Patient treated with corticoids or immunosuppressants in the month preceding inclusion * Patients treated with chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Horton's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de DIJON

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.